Tag Archives: Antitrust

Competition Law

CCI Order on Pharma Major Roche – III


CCI Order on Pharma Major Roche – I and CCI Order on Pharma Major Roche – II (Continued…) (ii) Whether or not Roche group tried to influence regulatory authorities so as to deny market access to the Informants? (Paragraphs 66 – 74) The Informants submitted various letters written by the Roche group to regulatory authorities. The Roche group, vide these letters, raised concerns regarding the clinical trials undertaken by the Informants for biosimilars. It tried to create a perception that…


Read More »
Competition Law

CCI Order on Pharma Major Roche – II


CCI Order on Pharma Major Roche – I and CCI Order on Pharma Major Roche – III (Continued…) c) Whether or not Roche group holds dominant position within the relevant market? (Paragraphs 52 – 58) Roche Group introduced Trastuzumab under the brand name HERCEPTIN in the year 2002. In the year 2012, it withdrew HERCEPTIN from Indian markets and introduced cheaper versions of Trastuzumab, viz., BICELTIS and HERCLON. As highlighted by the Informants, till February 2014, there was no other…


Read More »

SpicyIP Tidbit: IPXI releases latest edition of its Rulebook.


The IPXI (Intellectual Property Exchange International) is the world’s first financial exchange for licensing and trading intellectual property rights. My previous post on this can be found here.  The IPXI, last week, released the Rulebook that is to govern its first offerings.  This Rulebook is the product of interactions among  the various members of the IPXI which includes many IP owners as well. This Rulebook, which includes the additions recommended by the IPXI Rules Committee,(which is composed of the representatives…


Read More »

US Department of Justice conducts review of IPXI


A press release issued by IPXI, Intellectual Property Exchange International, Inc., the world’s first financial exchange for licensing and trading intellectual property rights, brought to our attention, the eight month long review of IPXI conducted by the Antitrust Division of the United States Department of Justice.  After the completion of the review, the DoJ has, according to the press release, issued its BRL (Business Review Letter) which apparently is in favour of the IPXI Licensing Model.  IPXI, is an exchange that has…


Read More »